11/4
10:23 am
cydy
CytoDyn Phase 2 study of leronlimab cleared by FDA [Seeking Alpha]
Medium
Report
CytoDyn Phase 2 study of leronlimab cleared by FDA [Seeking Alpha]
11/4
08:30 am
cydy
CytoDyn Announces FDA Clearance of Its Phase II Oncology Trial
Medium
Report
CytoDyn Announces FDA Clearance of Its Phase II Oncology Trial
10/30
08:30 am
cydy
CytoDyn Appoints Dr. Melissa Palmer, M.D., as Lead Consultant in Hepatology; Announces Follow-Up Inflammation Studies with SMC Laboratories
Low
Report
CytoDyn Appoints Dr. Melissa Palmer, M.D., as Lead Consultant in Hepatology; Announces Follow-Up Inflammation Studies with SMC Laboratories
10/8
08:36 am
cydy
CytoDyn Appoints Dr. Max Lataillade as Senior Vice President and Head of Clinical Development [Yahoo! Finance]
Low
Report
CytoDyn Appoints Dr. Max Lataillade as Senior Vice President and Head of Clinical Development [Yahoo! Finance]
10/8
08:30 am
cydy
CytoDyn Appoints Dr. Max Lataillade as Senior Vice President and Head of Clinical Development
Low
Report
CytoDyn Appoints Dr. Max Lataillade as Senior Vice President and Head of Clinical Development
10/7
11:07 am
cydy
CytoDyn Announces Abstract that Highlights Leronlimab's Potential in Mediating ART-Free Viral Control in Infant Rhesus Macaques [Yahoo! Finance]
Low
Report
CytoDyn Announces Abstract that Highlights Leronlimab's Potential in Mediating ART-Free Viral Control in Infant Rhesus Macaques [Yahoo! Finance]
10/7
11:05 am
cydy
CytoDyn Announces Abstract that Highlights Leronlimab’s Potential in Mediating ART-Free Viral Control in Infant Rhesus Macaques
Low
Report
CytoDyn Announces Abstract that Highlights Leronlimab’s Potential in Mediating ART-Free Viral Control in Infant Rhesus Macaques
10/4
08:30 am
cydy
CytoDyn Engages Syneos Health as CRO For Its Phase II Oncology Trial
Medium
Report
CytoDyn Engages Syneos Health as CRO For Its Phase II Oncology Trial
9/24
08:30 am
cydy
CytoDyn Announces Preliminary Findings in Study with SMC Laboratories
High
Report
CytoDyn Announces Preliminary Findings in Study with SMC Laboratories
9/9
08:30 am
cydy
September 2024 Letter to Shareholders
Medium
Report
September 2024 Letter to Shareholders
8/23
08:30 am
cydy
CytoDyn Engages Leading CRO For Phase II Inflammation Trial
Medium
Report
CytoDyn Engages Leading CRO For Phase II Inflammation Trial